tbuckley/cabot-search huggingface dataset:
Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis
Authors: Ashar Dhana, Yohhei Hamada, Andre P Kengne, Andrew D Kerkhoff, Molebogeng X Rangaka, Tamara Kredo, Annabel Baddeley, Cecily Miller, Ankur Gupta-Wright, Katherine Fielding, Robin Wood, Helena Huerga, Sekai Chenai Mathabire Rücker, Christine Heidebrecht, Douglas Wilson, Stephanie Bjerrum, Isik S Johansen, Swe Swe Thit, Mar Mar Kyi, Josh Hanson, David A Barr, Graeme Meintjes, Gary Maartens
Journal: The Lancet HIV (2022)

Since 2011, WHO has recommended that HIV-positive inpatients be routinely screened for tuberculosis with the WHO four-symptom screen (W4SS) and, if screened positive, receive a molecular WHO-recommended rapid diagnostic test (eg, Xpert MTB/RIF [Xpert] assay). To inform updated WHO tuberculosis screening guidelines, we conducted a systematic review and individual participant data meta-analysis to assess the performance of W4SS and alternative screening tests to guide Xpert testing and compare the diagnostic accuracy of the WHO Xpert algorithm (ie, W4SS followed by Xpert) with Xpert for all HIV-positive inpatients.
TCTAP A-051 Early and Long-Term Outcome of Intravascular Ultrasonography-Guided Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction: A Network Meta-Analysis
Authors: Gusti Ngurah Prana Jagannatha, Nikita Toding Labi, Ketut Angga Aditya Putra Pramana, Yusra Pintaningrum
Journal: Journal of the American College of Cardiology (2022)
TCTAP A-047 Physician Preferences for Recommending Renal Denervation to Hypertensive Patients Is Influenced by Patients’ Antihypertensive Medication Nonadherence Due to Medication Side Effects
Authors: Tzung-Dau Wang, Roland E. Schmieder, David E. Kandzari, Ying-Hsiang Lee, Carlos F. Haro, Atul Pathak
Journal: Journal of the American College of Cardiology (2022)
TCTAP A-061 Left Atrial Appendage Occlusion With the WATCHMAN Device: Peri-Procedural Outcomes From the Prospective, Multicenter RECORD Registry
Authors: Chao Gao, Fangju Su, Jianzheng Liu, David R. Holmes, Patrick W. Serruys, Ling Tao
Journal: Journal of the American College of Cardiology (2022)
Metabolic changes favor the activity and heterogeneity of reactive astrocytes
Authors: Xiao-Yi Xiong, Yong Tang, Qing-Wu Yang
Journal: Trends in Endocrinology and Metabolism (2022)

Reactive astrocytes undergo morphological, molecular, metabolic, and functional remodeling in response to central nervous system (CNS) damage. However, we still know very little about how the metabolic switching of astrocytes influences, or is influenced by, reactive astrocytes in response to neurological diseases. In this review, we initially cover a brief introduction into reactive astrocyte function under pathological conditions. Subsequently, we summarize the emerging roles of glucose and lipid metabolism in reactive astrocytes in the context of CNS injury to provide a new insight into metabolic mechanisms of reactive astrocyte-mediated neuroprotection or damage. Finally, we propose that deciphering the mechanistic link between astrocyte heterogeneity metabolism and improved methods is an emerging frontier for the therapeutic investigation of CNS injury and disease.
TCTAP A-017 Periprocedural Myocardial Infarction or Injury in Novel Low-Speed Following High-Speed and Conventional High-Speed Rotational Atherectomy Technique for Heavily Calcified Coronary Artery Lesions – The PRIMO-ROTA Pilot Study
Authors: Mahesh Gurung, Anuruck Jeamanukoolkit, Wasant Soonfuang, Thotsaporn Morasert
Journal: Journal of the American College of Cardiology (2022)
Necrotic Plaques on the Ears of a Patient With COVID-19
Authors: Erika Tvedten, Tyler Marion, Kiran Motaparthi
Journal: JAMA Dermatology (2022)

A man in his 40s with a history of factor VII deficiency hemophilia presented with respiratory failure secondary to COVID-19, and developed erythematous and edematous necrotic plaques of the bilateral ears 3 days after admission. What is your diagnosis?
Impact of the multiscale viscoelasticity of quasi-2D self-assembled protein networks on stem cell expansion at liquid interfaces
Authors: Dexu Kong, Lihui Peng, Minerva Bosch-Fortea, Alexandra Chrysanthou, Cardee V.J-M. Alexis, Carlos Matellan, Ali Zarbakhsh, Giulia Mastroianni, Armando del Rio Hernandez, Julien E. Gautrot
Journal: Biomaterials (2022)

Although not typically thought to sustain cell adhesion and expansion, liquid substrates have recently been shown to support such phenotypes, providing protein nanosheets could be assembled at corresponding liquid-liquid interfaces. However, the precise mechanical properties required from such quasi-2D nanoassemblies and how these correlate with molecular structure and nanoscale architecture has remained unclear. In this report, we screen a broad range of surfactants, proteins, oils and cell types and correlate interfacial mechanical properties with stem cell expansion. Correlations suggest an impact of interfacial viscoelasticity on the regulation of such behaviour. We combine interfacial rheology and magnetic tweezer-based interfacial microrheology to characterise the viscoelastic profile of protein nanosheets assembled at liquid-liquid interfaces. Based on neutron reflectometry and transmission electron microscopy data, we propose that the amorphous nanoarchitecture of quasi-2D protein nanosheets controls their multi-scale viscoelasticity which, in turn, correlates with cell expansion. This understanding paves the way for the rational design of protein nanosheets for microdroplet and bioemulsion-based stem cell manufacturing and screening platforms.
Association of State COVID-19 Vaccination Prioritization With Vaccination Rates Among Incarcerated Persons
Authors: Breanne E. Biondi, Kathryn M. Leifheit, Carmen R. Mitchell, Alexandra Skinner, Lauren Brinkley-Rubinstein, Julia Raifman
Journal: JAMA Network Open (2022)

rollout, availability, or incarcerated persons' preference.Distrust of staff is common in prisons, and how to encourage vaccination among incarcerated persons should be considered.Our analysis only included states that reported full doses of vaccination and thus may not be generalizable to the US prison population.Better data transparency, including full COVID-19 vaccinations and vaccinations by race and ethnicity, is needed to evaluate vaccinations in prisons.
Seeing me as high functioning masks my difficulties
Authors: Helen Wolfe
Journal: BMJ (2022)

Seeing me as high functioning masks my difficultiesHelen Wolfe explains the challenges of navigating the health system as an autistic person Helen WolfeEarlier this year, at the age of 25, I received a diagnosis of autism.The years leading up to my diagnosis were a mixture of academic success and increasingly frequent episodes of mental illness.
TCTAP C-084 Percutaneous Coronary Intervention in an Occluded Saphenous Vein Graft
Authors: Adelyn Nisha Henry, Hou Tee Lu, Kumutha Gobal, Vicknesan Kulasingham, Heng Shee Kim, Choon Keong Tee
Journal: Journal of the American College of Cardiology (2022)
HIF-2α-targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma
Authors: Minjiang Chen, Gaofeng Shu, Xiuling Lv, Xiaoling Xu, Chenying Lu, Enqi Qiao, Shiji Fang, Lin Shen, Nannan Zhang, Jun Wang, Chunmiao Chen, Jingjing Song, Zhuang Liu, Yongzhong Du, Jiansong Ji
Journal: Biomaterials (2022)
High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial
Authors: Almudena Zapatero, Araceli Guerrero, Xavier Maldonado, Ana Álvarez, Carmen González San-Segundo, María Ángeles Cabeza Rodríguez, Josep María Solé, Agustí Pedro Olivé, Francesc Casas, Ana Boladeras, Carmen Martín de Vidales, María Luisa Vázquez de la Torre, Susana Vara, Juan Luis Sanz, Felipe A Calvo
Journal: The Lancet Oncology (2022)
Monoclonal antibodies for malaria prevention
Authors: Maya Aleshnick, Melina Florez-Cuadros, Thomas Martinson, Brandon K. Wilder
Journal: Molecular Therapy (2022)

Monoclonal antibodies are highly specific proteins that are cloned from a single B cell and bind to a single epitope on a pathogen. These laboratory-made molecules can serve as prophylactics or therapeutics for infectious diseases and have an impressive capacity to modulate the progression of disease, as demonstrated for the first time on a large scale during the COVID-19 pandemic. The high specificity and natural starting point of monoclonal antibodies afford an encouraging safety profile, yet the high cost of production remains a major limitation to their widespread use. While a monoclonal antibody approach to abrogating malaria infection is not yet available, the unique life cycle of the malaria parasite affords many opportunities for such proteins to act, and preliminary research into the efficacy of monoclonal antibodies in preventing malaria infection, disease, and transmission is encouraging. This review examines the current status and future outlook for monoclonal antibodies against malaria in the context of the complex life cycle and varied antigenic targets expressed in the human and mosquito hosts, and provides insight into the strengths and limitations of this approach to curtailing one of humanity's oldest and deadliest diseases. Monoclonal antibodies are highly specific proteins that are cloned from a single B cell and bind to a single epitope on a pathogen. These laboratory-made molecules can serve as prophylactics or therapeutics for infectious diseases and have an impressive capacity to modulate the progression of disease, as demonstrated for the first time on a large scale during the COVID-19 pandemic. The high specificity and natural starting point of monoclonal antibodies afford an encouraging safety profile, yet the high cost of production remains a major limitation to their widespread use. While a monoclonal antibody approach to abrogating malaria infection is not yet available, the unique life cycle of the malaria parasite affords many opportunities for such proteins to act, and preliminary research into the efficacy of monoclonal antibodies in preventing malaria infection, disease, and transmission is encouraging. This review examines the current status and future outlook for monoclonal antibodies against malaria in the context of the complex life cycle and varied antigenic targets expressed in the human and mosquito hosts, and provides insight into the strengths and limitations of this approach to curtailing one of humanity's oldest and deadliest diseases.
TCTAP A-002 Prognostic Relevance of High-Risk Plaque Features in Guiding Treatment Strategy
Authors: Seokhun Yang, Doyeon Hwang, Joo Myung Lee, Eun-Seok Shin, Chang-Wook Nam, Joon-Hyung Doh, Jinlong Zhang, Hitoshi Matsuo, Takashi Kubo, Tsunekazu Kakuta, Bon-Kwon Koo
Journal: Journal of the American College of Cardiology (2022)
Suboptimal Antispike Antibody Levels Following Vaccination in Recipients of Solid Organ Transplant—Variance of Concern
Authors: Alan Koff, Maricar Malinis
Journal: JAMA Network Open (2022)

Kasama Manothummetha, MD; Nipat Chuleerarux, MD; Anawin Sanguankeo, MD, MPH; Olivia S. Kates, MD, MA; Nattiya Hirankarn, MD, PhD; Achitpol Thongkam, MD; M. Veronica Dioverti-Prono, MD; Pattama Torvorapanit, MD, MSc; Nattapong Langsiri, BSc; Navaporn Worasilchai, PhD; Chatphatai Moonla, MD, MSc; Rongpong Plongla, MD, MSc; William M Garneau, MD, MPH; Ariya Chindamporn, PhD; Pitchaphon Nissaisorakarn, MD; Tany Thaniyavarn, MD; Saman Nematollahi, MD, MEHP; Nitipong Permpalung, MD, MPH
TCTAP C-111 Successful “Ping-pong” Technique by Placing a Polytetrafluoroethylene-Covered Stent Followed by Inflation of Ryusei, a Perfusion Balloon for Type-3 Perforation at Proximal Right Coronary Artery Complicated Immediately After High-Pressure Dilations Inside Xience Skypoints
Authors: Hironori Kajitani, Tetsuya Ishikawa, Kahoko Mori, Hidehiko Nakamura, Hideyuki Aoki, Yukiko Mizutani, Tatsuhiko Ito, Yuta Kimura, Yuta Kikuchi, Tomoaki Ukaji, Kota Yamada, Itaru Hisauchi, Shiro Nakahara, Yuji Itabashi, Sayuki Kobayashi, Isao Taguchi
Journal: Journal of the American College of Cardiology (2022)
TCTAP A-026 Impact of Geographic Disparity on 10-Year Mortality in the SYNTAXES Trial, According to the SYNTAX Score II 2020 and Applying Machine Learning (Gradient Boosting Model)
Authors: Shigetaka Kageyama, Kai Ninomiya, Shinichiro Masuda, Nozomi Kotoku, Yoshinobu Onuma, Patrick W. Serruys
Journal: Journal of the American College of Cardiology (2022)
Metabolic Intervention Nanoparticles for Triple‐Negative Breast Cancer Therapy via Overcoming FSP1‐Mediated Ferroptosis Resistance
Authors: Jie Yang, Zengguang Jia, Jun Zhang, Xiuhua Pan, Yawen Wei, Siyu Ma, Ning Yang, Zengyi Liu, Qi Shen
Journal: Advanced Healthcare Materials (2022)

Triple-negative breast cancer (TNBC) patients have a predisposition to poor prognosis due to the strong malignancy. Ferroptosis, a new form of cell death, is a candidate treatment for TNBC owing to its effectiveness in killing cancer cells. However, some TNBC cells exhibit an abnormal tumor metabolism, especially the ferroptosis suppressor protein 1 (FSP1)-mediated ubiquinone redox metabolism, which can promote ferroptosis resistance. Here, rosuvastatin (RSV) is encapsulated in silk fibroin (SF) nanoparticle (designated as Cu-SF(RSV) NPs) for TNBC inhibition by overcoming FSP1-mediated ferroptosis resistance. RSV intervenes in metabolic mevalonate pathway to disturb the redox homeostasis regulated by CoQ/FSP1 axis, thereby overcoming ferroptosis resistance. Besides, Cu-SF(RSV) NPs can generate reactive oxygen species and deplete glutathione to facilitate redox stress, thereby amplifying ferroptosis effect. Thus, it is anticipated that the metabolic intervention nanoparticles, Cu-SF(RSV) NPs, can be exploited as a promising therapeutic platform for clinical TNBC treatment.
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
Authors: Xinxue Liu, Alasdair P S Munro, Shuo Feng, Leila Janani, Parvinder K Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Wanwisa Dejnirattisai, Kate Dodd, Yvanne Enever, Ehsaan Qureshi, Anna L. Goodman, Christopher A Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A. van der Klaauw, Jonathan Kwok, Vincenzo Libri, Martin J Llewelyn, Alastair C McGregor, Angela M. Minassian, Patrick Moore, Mehmood Mughal, Yama F Mujadidi, Kyra Holliday, Orod Osanlou, Rostam Osanlou, Daniel R Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Teona Serafimova, Dinesh Saralaya, Gavin R Screaton, Sunil Sharma, Ray Sheridan, Ann Sturdy, Piyada Supasa, Emma C Thomson, Shirley Todd, Chris Twelves, Robert C. Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Teresa Lambe, Jonathan S Nguyen-Van-Tam, Victoria Cornelius, Matthew D Snape, Saul N Faust
Journal: Journal of Infection (2022)

To evaluate the persistence of immunogenicity three months after third dose boosters.
TCTAP C-025 Third In-Stent Restenosis in 5 Years - Are We Doing Enough? Role of Intravascular Ultrasound and Lithotripsy in Severely Calcified ISR
Authors: Afif Ashari, Faten Aqilah Aris, Yuen Han Lim, Azhari Rosman
Journal: Journal of the American College of Cardiology (2022)
OGA activated glycopeptide-based nano-activator to activate PKM2 tetramerization for switching catabolic pathways and sensitizing chemotherapy resistance
Authors: Da-Yong Hou, Wu-Yi Xiao, Jia-Qi Wang, Muhammad Yaseen, Zhi-Jia Wang, Yue Fei, Man-Di Wang, Lu Wang, Hui Wang, Xinghua Shi, Meng-meng Cai, Hai-Tao Feng, Wanhai Xu, Li-Li Li
Journal: Biomaterials (2022)
Classification of<i>KRAS</i>-Activating Mutations and the Implications for Therapeutic Intervention
Authors: Christian Johnson, Deborah L. Burkhart, Kevin M. Haigis
Journal: Cancer Discovery (2022)

Abstract Members of the family of RAS proto-oncogenes, discovered just over 40 years ago, were among the first cancer-initiating genes to be discovered. Of the three RAS family members, KRAS is the most frequently mutated in human cancers. Despite intensive biological and biochemical study of RAS proteins over the past four decades, we are only now starting to devise therapeutic strategies to target their oncogenic properties. Here, we highlight the distinct biochemical properties of common and rare KRAS alleles, enabling their classification into functional subtypes. We also discuss the implications of this functional classification for potential therapeutic avenues targeting mutant subtypes. Significance: Efforts in the recent past to inhibit KRAS oncogenicity have focused on kinases that function in downstream signal transduction cascades, although preclinical successes have not translated to patients with KRAS-mutant cancer. Recently, clinically effective covalent inhibitors of KRASG12C have been developed, establishing two principles that form a foundation for future efforts. First, KRAS is druggable. Second, each mutant form of KRAS is likely to have properties that make it uniquely druggable.
Exendin-(9-39) Effects on Glucose and Insulin in Children With Congenital Hyperinsulinism During Fasting and During a Meal and a Protein Challenge
Authors: Darko Stefanovski, Mary E. Vajravelu, Stephanie Givler, Diva D. De León
Journal: Diabetes Care (2022)

OBJECTIVE The aim of this study was to assess whether exendin-(9-39) will increase fasting and postprandial plasma glucose and decrease the incidence of hypoglycemia in children with hyperinsulinism (HI). RESEARCH DESIGN AND METHODS This was an open-label, four-period crossover study. In periods 1 and 2, the effect of three different dosing regimens of exendin-(9-39) (group 1, 0.28 mg/kg; group 2, 0.44 mg/kg; group 3, 0.6 mg/kg) versus vehicle on fasting glucose was assessed in 16 children with HI. In periods 3 and 4, a subset of eight subjects received either vehicle or exendin-(9-39) (0.6 mg/kg) during a mixed-meal tolerance test (MMTT) and an oral protein tolerance test (OPTT). RESULTS Treatment group 2 showed 20% (P = 0.037) increase in the area under the curve (AUC) of fasting glucose. A significant increase in AUC of glucose was also observed during the MMTT and OPTT; treatment with exendin-(9-39) resulted in 28% (P ≤ 0.001) and 30% (P = 0.01) increase in AUC of glucose, respectively. Fasting AUC of insulin decreased by 57% (P = 0.009) in group 3. In contrast, AUC of insulin was unchanged during the MMTT and almost twofold higher (P = 0.004) during the OPTT with exendin-(9-39) treatment. In comparison with vehicle, infusion of exendin-(9-39) resulted in significant reduction in likelihood of hypoglycemia in group 2, by 76% (P = 0.009), and in group 3, by 84% (P = 0.014). Administration of exendin-(9-39) during the OPTT resulted in 82% (P = 0.007) reduction in the likelihood of hypoglycemia. CONCLUSIONS These results support a therapeutic potential of exendin-(9-39) to prevent fasting and protein-induced hypoglycemia in children with HI.
The effect of conditional cash transfers on the control of neglected tropical disease: a systematic review
Authors: Aaminah Ahmed, Dagfinn Aune, Paolo Vineis, Julia M Pescarini, Christopher Millett, Thomas Hone
Journal: The Lancet Global Health (2022)

Neglected tropical diseases (NTDs) are diseases of poverty and affect 1·5 billion people globally. Conditional cash transfer (CCTs) programmes alleviate poverty in many countries, potentially contributing to improved NTD outcomes. This systematic review examines the relationship between CCTs and screening, incidence, or treatment outcomes of NTDs.In this systematic review we searched MEDLINE, Embase, Lilacs, EconLit, Global Health, and grey literature websites on Sept 17, 2020, with no date or language restrictions. Controlled quantitative studies including randomised controlled trials (RCTs) and observational studies evaluating CCT interventions in low-income and middle-income countries were included. Any outcome measures related to WHO's 20 diseases classified as NTDs were included. Studies from high-income countries were excluded. Two authors (AA and TH) extracted data from published studies and appraised risk of biases using the Risk of Bias in Non-Randomised Studies of Interventions and Risk of Bias 2 tools. Results were analysed narratively. This study is registered with PROSPERO, CRD42020202480.From the search, 5165 records were identified; of these, 11 studies were eligible for inclusion covering four CCTs in Brazil, the Philippines, Mexico, and Zambia. Most studies were either RCTs or quasi-experimental studies and ten were assessed to be of moderate quality. Seven studies reported improved NTD outcomes associated with CCTs, in particular, reduced incidence of leprosy and increased uptake of deworming treatments. There was some evidence of greater benefit of CCTS in lower socioeconomic groups but subgroup analysis was scarce. Methodological weaknesses include self-reported outcomes, missing data, improper randomisation, and differences between CCT and comparator populations in observational studies. The available evidence is currently limited, covering a small proportion of CCTs and NTDs.CCTs can be associated with improved NTD outcomes, and could be driven by both improvements in living standards from cash benefits and direct health effects from conditionalities related to health-care use. This evidence adds to the knowledge of health-improving effects from CCTs in poor and vulnerable populations.None.
Human enteric viruses autonomously shape inflammatory bowel disease phenotype through divergent innate immunomodulation
Authors: Fatemeh Adiliaghdam, Hajera Amatullah, Sreehaas Digumarthi, Tahnee L. Saunders, Raza-Ur Rahman, Lai Ping Wong, Ruslan Sadreyev, Lindsay Droit, Jean Paquette, Philippe Goyette, John D. Rioux, Richard Hodin, Kathie A. Mihindukulasuriya, Scott A. Handley, Kate L. Jeffrey
Journal: Science Immunology (2022)

Altered enteric microorganisms in concert with host genetics shape inflammatory bowel disease (IBD) phenotypes. However, insight is limited to bacteria and fungi. We found that eukaryotic viruses and bacteriophages (collectively, the virome), enriched from non-IBD, noninflamed human colon resections, actively elicited atypical anti-inflammatory innate immune programs. Conversely, ulcerative colitis or Crohn's disease colon resection viromes provoked inflammation, which was successfully dampened by non-IBD viromes. The IBD colon tissue virome was perturbed, including an increase in the enterovirus B species of eukaryotic picornaviruses, not previously detected in fecal virome studies. Mice humanized with non-IBD colon tissue viromes were protected from intestinal inflammation, whereas IBD virome mice exhibited exacerbated inflammation in a nucleic acid sensing-dependent fashion. Furthermore, there were detrimental consequences for IBD patient-derived intestinal epithelial cells bearing loss-of-function mutations within virus sensor MDA5 when exposed to viromes. Our results demonstrate that innate recognition of IBD or non-IBD human viromes autonomously influences intestinal homeostasis and disease phenotypes. Thus, perturbations in the intestinal virome, or an altered ability to sense the virome due to genetic variation, contribute to the induction of IBD. Harnessing the virome may offer therapeutic and biomarker potential.